- Home
- BEAM vs TVTX Comparison
BEAM vs TVTX Comparison
Compare BEAM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- TVTX
- Stock Information
- Founded
- BEAM 2017
- TVTX 2008
- Country
- BEAM United States
- TVTX United States
- Employees
- BEAM N/A
- TVTX N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- TVTX Health Care
- Exchange
- BEAM Nasdaq
- TVTX Nasdaq
- Market Cap
- BEAM 1.8B
- TVTX 1.7B
- IPO Year
- BEAM 2020
- TVTX N/A
- Fundamental
- Price
- BEAM $17.41
- TVTX $20.02
- Analyst Decision
- BEAM Strong Buy
- TVTX Strong Buy
- Analyst Count
- BEAM 11
- TVTX 14
- Target Price
- BEAM $48.90
- TVTX $33.31
- AVG Volume (30 Days)
- BEAM 2.2M
- TVTX 1.5M
- Earning Date
- BEAM 05-06-2025
- TVTX 05-01-2025
- Dividend Yield
- BEAM N/A
- TVTX N/A
- EPS Growth
- BEAM N/A
- TVTX N/A
- EPS
- BEAM N/A
- TVTX N/A
- Revenue
- BEAM $63,578,000.00
- TVTX $273,533,000.00
- Revenue This Year
- BEAM N/A
- TVTX $68.31
- Revenue Next Year
- BEAM $6.32
- TVTX $55.65
- P/E Ratio
- BEAM N/A
- TVTX N/A
- Revenue Growth
- BEAM N/A
- TVTX 75.65
- 52 Week Low
- BEAM $13.53
- TVTX $6.01
- 52 Week High
- BEAM $35.25
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- BEAM 43.14
- TVTX 58.32
- Support Level
- BEAM $15.51
- TVTX $19.65
- Resistance Level
- BEAM $20.90
- TVTX $22.07
- Average True Range (ATR)
- BEAM 1.22
- TVTX 1.11
- MACD
- BEAM -0.03
- TVTX 0.31
- Stochastic Oscillator
- BEAM 35.25
- TVTX 69.58
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.